NetworkNewsBreaks – Lexaria Bioscience Corp.’s
Post# of 420
(Total Views: 112)
Posted On: 10/02/2023 5:09:52 PM
NetworkNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-Nicotine Pouch Demonstrates Advantages over Competition
Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently reported results from its human oral nicotine study NIC-H22-1, comparing Lexaria’s DehydraTECH(TM)-nicotine tobacco-free pouch to world-leading brands ZYN(R) and on! “Using measurements to determine the median time required to reach comparable nicotine concentrations within the bloodstream (‘Tmax’), Lexaria exhibited higher levels of certain pleasurable effects over the competition. DehydraTECH also provided the lowest frequency of unwanted negative effects, including moderate to severe nausea, demonstrating benefits from Lexaria’s formulation,” a recent article reads. “We’ve always had an overwhelming determination and fierce conviction that we can make the world a better place and reduce the carnage caused by smoked cigarettes, and now we have human study data that demonstrates advantages of DehydraTECH-processed nicotine relative to the competitive landscape,” Lexaria CEO Chris Bunka is quoted as saying.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently reported results from its human oral nicotine study NIC-H22-1, comparing Lexaria’s DehydraTECH(TM)-nicotine tobacco-free pouch to world-leading brands ZYN(R) and on! “Using measurements to determine the median time required to reach comparable nicotine concentrations within the bloodstream (‘Tmax’), Lexaria exhibited higher levels of certain pleasurable effects over the competition. DehydraTECH also provided the lowest frequency of unwanted negative effects, including moderate to severe nausea, demonstrating benefits from Lexaria’s formulation,” a recent article reads. “We’ve always had an overwhelming determination and fierce conviction that we can make the world a better place and reduce the carnage caused by smoked cigarettes, and now we have human study data that demonstrates advantages of DehydraTECH-processed nicotine relative to the competitive landscape,” Lexaria CEO Chris Bunka is quoted as saying.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LEXX) Stock Research Links
Scroll down for more posts ▼